The emerging pathogens Marburg virus and Ebola (EBO) negative experimental evidence of efficacy in a primate model. The development of effective therapy must be a top priority virus cause very severe hemorrhagic fevers and mortality as high as 90%. As stated by Piot et al. [1] , ''The evolution of in preparing to deal with subsequent outbreaks. Antiviral therapy offers the possibility of reducing morbidity, disease often seems inexorable and invariable.'' First recognized in 1976, EBO outbreaks in Africa have been associated mortality, and transmission by prophylaxis of high-risk contacts. Discovery of an active antiviral compound by random with high rates of morbidity and mortality. Almost nothing is known about the natural histories of these viruses, despite the screening requires either screening tens of thousands of compounds, which is impractical in a maximum-containment biofield investigations (designed to identify risk factors and reservoirs) that were done after each major outbreak. There are no safety level 4 (BSL-4) environment, or considerable luck. Selection of compounds with a higher probability of antiviral specific treatments for Marburg and EBO viral hemorrhagic fevers. Ribavirin, an antiviral drug used to treat several other activity against filoviruses can be inferred from the activity of the compound against other viruses with similar molecular hemorrhagic fevers, has no in vitro effect on Marburg and EBO viruses, failed to protect in multiple primate studies, and is targets. Molecular targets for drug intervention are steps central to viral replication, whose inhibition selectively blocks viral unlikely to have any clinical value to human patients [2] . Human convalescent plasma containing antibodies has been used replication, either because normal cells lack the equivalent target or the cellular analogue of the target is not inhibited within for treatment in the past, despite the lack of coherent clinical or experimental data regarding its use. Equine IgG with highthe range of concentrations that inhibits the viral target. The availability of the full-length sequence of EBO [5] has allowed titer neutralizing antibodies to EBO virus protected guinea pigs and baboons but failed to protect rhesus monkeys infected the identification of homologous sequences in other viruses and the determination of potential shared molecular targets. with an EBO virus isolated from the 1995 Zaire outbreak [3] . Similarly, human interferon was used in 1 patient [4] despite Filoviruses share similar molecular organization with rhabdoand paramyxoviruses but are closer to the family paramyxoviridae, as determined on the basis of several of our observations. Several targets appear to be functionally identical between EBO that of the host cell -encoded enzyme (reviewed in [8] EBO-Z viruses (MOI, 0.01 pfu/cell) in 50 mL, and four rows were sham-infected with subcomplete medium (50 mL) as controls for times intracerebrally in suckling mice and then once in Vero cells [9] . EBO-Z viruses (1976 and 1995 strains) that had been passaged drug toxicity. The plate was incubated for 6-7 days in a CO 2 incubator at 37ЊC until cytopathic effect (CPE) reached 3/ in twice in Vero cells were provided by Peter Jahrling (USAMRIID). The viruses were amplified in Vero E6 cells, and the supernatant control wells. Viable cells were assayed by using an MTT-based procedure was collected to produce stocks of EBO-Z '76 Vp2, EBO-Z '76 Mp3 Vp2, and EBO-Z '95 Vp3. The derivation and biologic propthat measures the conversion of colorless MTT tetrazolium to colored MTT formazan by mitochondrial enzymes in the electron erties of ''mouse-adapted virus,'' a doubly plaque-purified, ninth mouse-passage virus derived from the 1976 strain of EBO-Z and transport chain [13] . Previously filtered MTT (0.83 mg/mL final concentration in subcomplete medium) was then added to the plate designated EBO-Z '76 Mp3 Vp2 Mp9 GH, is described elsewhere in this supplement [10] . The E6 line of Vero African green monkey and incubated for 2 h at 37ЊC. Medium was then removed, and the insoluble reaction product was solubilized by adding 100 mL kidney cells, Vero C1008 (ATCC CRL 1586); DBS-FRhL (ATCC CL 160); LLC-MK 2 (ATCC CLL 7); MRC-5 (ATCC CCL 171); of DMSO. The plate was mixed on an orbital shaker until the reaction product was completely dissolved. The colored MTT SW13 (ATCC CLL 105); Vero 76 (ATCC CRL 1586); and BALB/ 3T3 clone A31 (ATCC CCL 163) were propagated in Eagle MEM formazan reaction product was measured at 570 nm with a Vmax ELISA reader (Molecular Devices, Menlo Park, CA), and data with Earle's salts, nonessential amino acids, 10% fetal bovine serum (FBS), glutamine, penicillin, and streptomycin; the same were captured on a computer for manipulation and analysis. The resulting dose-response curves were fitted to a four-parameter logit medium with only 2% FBS was used as replacement medium (subcomplete medium) after cell infection.
curve by use of a computer program (SOFTmax; Molecular Devices) to determine the IC 50 , the TC 50 (50% toxic concentration), Compounds. Carbocyclic adenosine (aristeromycin; Ca-Ado) was purchased from Sigma (St. Louis). Carbocyclic 3-deazaadeand the therapeutic index, which was calculated as TC 50 /IC 50 . Antiviral protection curves were corrected for toxicity, using a prenosine (3-deazaaristeromycin; Ca-c 3 Ado) [11] and (-)-9-[trans-2,trans -3 -dihydroxy -4 -(methyl) -cyclopent -4 -enyl] -3 -viously described toxicity curve [13] . zyme among the compounds tested, was the most effective at Npc A could Antiviral activity of SAH hydrolase inhibitors. An antiviral screening program previously identified anti-EBO activity of inhibit viral replication when administered every 12 h, but the lack of a functional immune system in these animals precluded a known inhibitor of SAH hydrolase [6] . Inhibition of EBO-Z replication in Vero E6 cells by a series of known SAH inhibia realistic evaluation of the compounds (data not shown). Pharmacokinetic and distribution studies [17, 18] in adult BALB/ tors is shown in figure 1 . Permissive Vero E6 monolayers were infected with EBO virus at a low MOI such that if viral c mice showed that Ca-c Ado treatment could be successfully initiated, we infected mice as above, and treatwith doses ranging from 0.03 to 20 mg/kg. A dose-dependent increase in mean time to death was seen as doses increased from ment at three dose levels was initiated on days 0, 1, 2, or 3 relative to virus challenge (see below; figure 3 ). Complete 0.08 to 0.3 mg/kg (table 2). Mice were completely protected by doses of §0.7 mg/kg. Drug was well tolerated at the highest protection occurred when treatment was initiated immediately and after 1 day of infection. Mice were significantly protected dose tested (20 mg/kg), which was 28 times the minimum protective dose. Some weight loss occurred during compound (90%) when treatment was begun on day 2. Other experiments showed that the liver had an average titer of 3 1 10 5 pfu/g dosing (days 01 to 8), but at doses õ2.2 mg/kg, animals returned to baseline weights during the subsequent 5 days. At virus and the spleen had 2 1 10 6 pfu/g. While controls died within a mean of 6.7 days, the only treated animal that died and above this dose, a less dramatic weight recovery was seen, but all animals remained healthy throughout the study period.
SAH hydrolase inhibitors tested could not completely inhibit viral replication (data not shown).

Evaluation of prophylactic administration of Ca
did so on day 15. Treatment (2.2 mg/kg) for 10 mice was initiated on day 3, when the liver had an average titer of 2 1 Infected, treated animals that survived were rechallenged with 100 pfu (3000 LD 50 ) of the same virus to obtain positive evi-10 7 pfu/g virus and the spleen had 2 1 10 8 pfu/g virus; 4 of the 10 mice survived. Toxicity, as judged by weight loss greater dence that they were infected in the experiment. All animals were protected, including animals in the higher-dose groups than that for untreated controls, was seen at the 20 mg/kg dose when treatment was begun on days 1 -3. Toxicity was also Treated survivors were rechallenged with 100 pfu (3000 LD 50 ) of virus and, once again, all animals were protected, demonstraseen with a 6.7-mg/kg dose when treatment was begun on day 3 (table 3) , which required a shorter treatment schedule. Because ting that they were infected. substantial infection of the liver occurred by this time, the lack of protection may have been due to altered compound Discussion metabolism or pharmacokinetics caused by reduced drug elimination, leading to toxic levels. We did not test lower doses of
The task of developing filovirus chemotherapy is complicated by the constraints imposed in conducting research under compound, so we do not know if this was the maximum protection possible.
BLS-4 conditions, the limited information available on the mechanism of viral replication, and the lack of closely related When treatment was initiated on day 3, higher doses of drug resulted in a significant increase in mean time to death. None viruses of lower pathogenicity that could serve as surrogates for drug studies. The recognition that filoviruses share similar of the animals had signs of disease at the end of the treatment period; however, they all died 5 -6 days after cessation of gene organization with paramyxoviruses provided a rationale for selecting compounds for initial testing. Inhibition of EBO treatment. Two treated moribund animals were killed 5 days after the end of treatment; both had virus titers in the liver that virus replication by several compounds known to inhibit SAH hydrolase led us to investigate a series of known inhibitors, were 2 logs lower than those expected of terminal animals, suggesting that viral replication initially may have been parnine of which we report here. All SAH hydrolase inhibitors tested inhibited viral replication, and where their inhibition tially controlled but resumed after treatment was discontinued. Ado administered every 8 h at dose that provided maximum survival; छ Å mean viremia (pfu/ mL); ᭺ Å mean liver titer (pfu/g tissue); ᭝ Å mean spleen titer (pfu/g tissue). Virus titers were mean for 4 animals (2 at each time point in 2 separate experiments). Virus titers were determined as described in [10] .
/ 9d49$$se39 01-05-99 13:32:19 jinfal UC: J Infect constant was known [19] , it correlated with the EBO IC 50 (data Our initial concern was that the model would present a formidable challenge for antiviral intervention. The design of initial not shown). The specificity of inhibition was shown by the lack of antiviral activity of guanosine dialdehyde (not an inhibitor of prophylactic studies had the benefit of appropriate pharmacokinetic studies that established the requirement for dosing at least SAH hydrolase) compared with that of adenosine dialdehyde. SAH hydrolase has been recognized as an important target for every 8 h. The treatment duration was empirically selected as 1.5 times the expected mean time to death, and this parameter antiviral drug development for some time [8] .
had not been evaluated to determine if this is optimal. Studies Antiviral activity of Ca-c 3 Ado in vitro and in vivo was in the to determine the therapeutic window for intervention showed range reported for other viruses, including respiratory syncytial that treatment could be initiated quite late in the disease process virus and parainfluenza virus [7, 20] . Initial evaluation with on day 3, when 10 7 -10 8 pfu/g virus was present in organs. dosing either once or twice per day demonstrated moderate These animals were symptomatic when treatment was initiated antiviral activity [20] . Studies with c 3 -Npc A in a SCID mouse and recovered slowly over the next 2 weeks. model showed that while dosing every 12 h only reduced virus titers by 1 -2 logs, dosing every 8 h reduced the titer by ú6
Later times of initiation of therapy have not yet been investigated because increasing drug toxicity, observed when treatlogs (unpublished results). Ca-c 3 Ado was initially evaluated in a SCID mouse model, in which it significantly slowed the ment was initiated on day 2 or 3, suggested that either sufficient organ damage occurred to limit drug dosage due to increased rate of viral replication and increased the mean time to death (unpublished observations); however, this model was far from sensitivity or that drug pharmacokinetics had been altered because the rate of drug elimination had changed. Elimination of ideal for drug evaluation.
Ca-c 3 Ado from tissues of healthy mice is rapid and correlates Our efforts to adapt EBO virus to produce lethal disease in with the appearance of a metabolite in serum that has yet to immunocompetent adult mice by serial passage is published be identified [17] . Significant liver necrosis was seen by days elsewhere in this supplement [10] . Adult BALB/c mice infected 2 to 3. The liver is involved in the clearance of many nucleoside by ip inoculation with 30 LD 50 of mouse-adapted EBO virus analogues. Additional studies of drug levels in mice 2 -4 days become ill within 3 -4 days and uniformly die on days 5 -7. after infection will be required to design studies to determine The virus infects cells of the mononuclear phagocytic system, how late in the infection process treatment can be initiated. hepatocytes, and endothelial cells. Pathologic changes in the Nevertheless, Ca-c 3 Ado is the first compound reported to cure liver and spleen resembled those seen in EBO-Z infection of animals from this otherwise lethal infection. humans and nonhuman primates. Viral replication is first detectable on day 2 and leads to a rapid rise of virus titers in SAH hydrolase is a highly conserved enzyme among species, and the virus IC 50 of SAH hydrolase inhibitors does not differ serum and tissues, reaching near maximum titers by day 4. This pathology resembles that observed in primates dying of significantly among cells derived from human, nonhuman primate, and murine tissues. Optimization of conditions for Ca-EBO infection [10] . While this is clearly a severe model of viral infection, it appears appropriate as a model for the human c
